Department for Medical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia.
J BUON. 2021 Sep-Oct;26(5):2183-2190.
Recommendations and guidelines consider cancer patients a high-priority population for COVID-19 immunization. Vaccination process in Serbia began in January 2021 with four available vaccines. We have conducted a cross-sectional study investigating cancer patients' acceptability of anti SARS-COV2 vaccines.
The study included 767 patients with solid and hematologic malignancies treated at the Oncology Institute of Vojvodina, Serbia. During July and August 2021 patients filled in an individual paper questionnaire on anti SARS-COV2 vaccination acceptance, preferences, side effects and information origin. Data on treatment phase, diagnosis and treatment was collected from electronic health records.
During the first six months of vaccination campaign in Serbia 41% (320/767) of the investigated oncology patients received COVID-19 vaccines. The median age of vaccinated patients was 65 years (28-84). Most of them (75%) were in active treatment of cancer. Half of the unvaccinated patients (52%) wish to get vaccinated after the end of their cancer treatment. Around 10% of the patients definitely refused vaccination. The majority of information on COVID-19 vaccines cancer patients got from their oncologist, television and newspapers. Side effects were reported by 10.93% of the patients after the first dose and 13,31% after the second dose. No serious side effects were reported.
We have confirmed that patients are reluctant of receiving vaccine due to fear of side effects, especially during the active cancer treatment. However, real-world evidence and clinical trials data have gathered enough evidence to reassure any doubts of the patients and their oncologists on safety and efficacy of anti SARS-COV2 vaccines.
建议和指南将癌症患者视为 COVID-19 疫苗接种的高优先级人群。塞尔维亚的疫苗接种工作于 2021 年 1 月开始，当时有四种可用的疫苗。我们进行了一项横断面研究，调查癌症患者对 SARS-CoV2 疫苗的接受程度。
该研究纳入了在塞尔维亚伏伊伏丁那肿瘤研究所接受治疗的 767 名实体瘤和血液恶性肿瘤患者。在 2021 年 7 月和 8 月期间，患者填写了一份关于 SARS-CoV2 疫苗接种接受度、偏好、副作用和信息来源的个人纸质问卷。从电子病历中收集了治疗阶段、诊断和治疗的数据。
在塞尔维亚疫苗接种运动的前六个月，767 名肿瘤患者中有 41%（320/767）接种了 COVID-19 疫苗。接种疫苗患者的中位年龄为 65 岁（28-84 岁）。他们中的大多数（75%）正在接受癌症的积极治疗。一半未接种疫苗的患者（52%）希望在癌症治疗结束后接种疫苗。约 10%的患者明确拒绝接种疫苗。癌症患者获得 COVID-19 疫苗信息的主要来源是他们的肿瘤医生、电视和报纸。接种第一剂疫苗后，有 10.93%的患者报告出现副作用，接种第二剂疫苗后，有 13.31%的患者报告出现副作用。没有报告严重的副作用。
我们已经证实，患者对接种疫苗犹豫不决，主要是因为担心副作用，尤其是在癌症治疗期间。然而，真实世界的证据和临床试验数据已经收集了足够的证据，以消除患者及其肿瘤医生对 SARS-CoV2 疫苗安全性和有效性的疑虑。
